Brief: Repare Therapeutics Reports Proof Of Concept For Lunresertib In Clinic
07/06/2023 21:35
June 7 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS REPORTS PROOF OF CONCEPT FOR
LUNRESERTIB
(RP-6306) IN CLINIC, INITIAL MONOTHERAPY DATA FROM PHASE 1
MYTHIC CLINICAL TRIAL AND EARLY INSIGHTS FROM ONGOING
COMBINATION TRIALS
* REPARE THERAPEUTICS- FINDINGS FROM ONGOING PHASE 1 MYTHIC
STUDY
DEMONSTRATED FAVORABLE & DISTINCTIVE TOLERABILITY PROFILE FOR
MONOTHERAPY LUNRESERTIB
* REPARE THERAPEUTICS- LOOK FORWARD TO REPORTING INITIAL
COMBINATION DATA OF LUNRESERTIB WITH CAMONSERTIB, AS WELL AS
LUNRESERTIB WITH GEMCITABINE IN Q4
Source text for Eikon: ID:nBw1B41yca
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln